Chinese Drug Shows Benefit in HER2-Low Breast Cancer

(MedPage Today) -- An investigational antibody-drug conjugate (ADC) significantly reduced the risk of disease progression or death in patients with HER2-low metastatic breast cancer, a Chinese phase III trial showed. The drug, trastuzumab rezetecan...